mesalamine has been researched along with Electron Transport Chain Deficiencies, Mitochondrial in 1 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haberman, Y | 1 |
| Karns, R | 1 |
| Dexheimer, PJ | 1 |
| Schirmer, M | 1 |
| Somekh, J | 1 |
| Jurickova, I | 1 |
| Braun, T | 1 |
| Novak, E | 1 |
| Bauman, L | 1 |
| Collins, MH | 1 |
| Mo, A | 1 |
| Rosen, MJ | 1 |
| Bonkowski, E | 1 |
| Gotman, N | 1 |
| Marquis, A | 1 |
| Nistel, M | 1 |
| Rufo, PA | 1 |
| Baker, SS | 1 |
| Sauer, CG | 1 |
| Markowitz, J | 1 |
| Pfefferkorn, MD | 1 |
| Rosh, JR | 1 |
| Boyle, BM | 1 |
| Mack, DR | 1 |
| Baldassano, RN | 1 |
| Shah, S | 1 |
| Leleiko, NS | 1 |
| Heyman, MB | 1 |
| Grifiths, AM | 1 |
| Patel, AS | 1 |
| Noe, JD | 1 |
| Aronow, BJ | 1 |
| Kugathasan, S | 1 |
| Walters, TD | 1 |
| Gibson, G | 1 |
| Thomas, SD | 1 |
| Mollen, K | 1 |
| Shen-Orr, S | 1 |
| Huttenhower, C | 1 |
| Xavier, RJ | 1 |
| Hyams, JS | 1 |
| Denson, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nicotinamide Riboside in Ulcerative Colitis[NCT05561738] | 40 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for mesalamine and Electron Transport Chain Deficiencies, Mitochondrial
| Article | Year |
|---|---|
Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Feces; Femal | 2019 |